New frontiers in obesity treatment: GLP-1 and nascent nutrient-stimulated hormone-based therapeutics
Special Feature: Antioxidant
5 Raparelli Valeria 6 Kautzky-Willer Alexandra 7 Herrero Maria Trinidad 8 Kublickiene Karolina 1, Heimbrger, O., Barany, P., Wennberg, L., Stenvinkel, P
Lars Fruergaard Jrgensen, Novo Nordisks chief executive, said: We are very satisfied with the sales growth in the first nine months of 2023, which is reflecting that more people than ever are benefiting from our innovative diabetes and obesity treatments. Novo is racing to keep up with demand, and said it would restrict supplies of Wegovy in the US
Glycine is an amino acid with calming properties that may help offset the insomnia some patients experience on tirzepatide